Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ: VIR )

7.340 -0.030 (-0.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Exposures COVID-19
Vir Biotech's HBV Candidates Show Positive Safety Profiles
Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) stock increased by 39.78% to $3.97 during Friday's regular session. The current volume of 48.4 million shares is 18988.... 
Via Benzinga
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
Exposures COVID-19
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating... 
Via Benzinga
Exposures COVID-19
Earnings Scheduled For May 6, 2021
Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion. • Cohen... 
Via Benzinga
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
15 Words From Vir Biotechnology's CEO May Mean Market Dominance
Vir's antibody treatment is addressing one of the biggest COVID challenges. 
Via The Motley Fool
Exposures COVID-19
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
Exposures COVID-19
Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ... 
Via Benzinga
Exposures COVID-19 Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 22.59% to $0.91 during Thursday's pre-market session. The company's market cap stands at $97.3 million.... 
Via Benzinga
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.... 
Via Benzinga
Market Briefing For Thursday, May 27
Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability. 
Via Talk Markets
GlaxoSmithKline - Vir Biotech's Antibody COVID-19 Treatment Wins CHMP's Positive Scientific Opinion
The European Medicines Agency’s advisory group, Committee for Human Medicinal Products (CHMP), has concluded that GlaxoSmithKline plc (NYSE: GSK) and Vir... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vir Biotechnology (NASDAQ:VIR) sha... 
Via Benzinga
Bill And Melinda Gates' Divorce News A Bull Case For GameStop? What You Need To Know
A post by a member of the Reddit investor forum r/GME in March that speculated billionaires were increasing their short positions in GameSt... 
Via Benzinga
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient... 
Via Benzinga
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B
From Brii Biosciences and Vir Biotechnology, Inc. and VBI Vaccines Inc.
Via Business Wire
Could Vir Biotechnology Be a Millionaire Maker Stock?
Vir is developing treatments in billion-dollar markets. 
Via The Motley Fool
Exposures COVID-19
Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?
One of the three clearly has the most upside potential. 
Via The Motley Fool
Exposures COVID-19
Vir Biotechnology vs. Sorrento Therapeutics: The Wisdom of Crowds Says...
Which stock has more potential for growth over the next year? Let's look to the stars for an answer. 
Via The Motley Fool
Exposures COVID-19
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.